A case of hepatitis in a patient receiving rituximab for ITP is reported. After an extensive workup, no infectious or autoimmune etiology could be found. The authors believe that this represents a case of drug-induced hepatitis, which has not been reported for this agent in the past.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/cbr.2010.0806 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Obinutuzumab-induced acute thrombocytopenia: a case report and literature review.
Front Oncol
December 2024
Department of Hematology, Peking University People's Hospital, National Clinical Research Center for Hematologic Diseases, Peking University Institute of Hematology, Beijing, China.
Background: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphomas. Thrombocytopenia typically occurs 1 to 2 weeks after administration. In rare cases, obinutuzumab can induce severe acute thrombocytopenia within days of infusion, a condition known as "obinutuzumab-induced acute thrombocytopenia (OIAT).
View Article and Find Full Text PDFRituximab-Associated Acute Ischemic Stroke in a Patient With Primary Angiitis of the Central Nervous System.
Cureus
October 2024
Department of Neurology, Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, TUR.
During or after rituximab treatment, various serious side effects may occur. Cerebrovascular diseases are relatively limited among these side effects, and whether they are contingent on rituximab treatment is unclear. This case report highlights an unusual and severe event after rituximab treatment.
View Article and Find Full Text PDF[Acquired thrombotic thrombocytopenic purpura with rituximab-induced serum sickness].
Rinsho Ketsueki
November 2024
Department of Hematology, Yokosuka Kyosai Hospital.
The patient was a 38-year-old man who was admitted to our hospital with fever, vomiting and unclear speech. Blood tests showed hemolytic anemia, thrombocytopenia, and elevated creatinine, and a Coombs test was negative. ADAMTS13 activity was <1% and ADAMTS13 inhibitor was 0.
View Article and Find Full Text PDFBackground: Cerebral venous sinus thrombosis has not been reported in anti-N-methyl-D-aspartate receptor-antibody encephalitis in the absence of an underlying thrombotic state while rituximab induced cerebral venous sinus thrombosis is rarely reported. We report a patient with anti-N-methyl-D-aspartate receptor-antibody encephalitis without a prothrombotic state who developed cerebral venous sinus thrombosis following rituximab treatment.
Case Presentation: A 15-year-old Sri Lankan girl who had been in remission following an episode of anti-N-methyl-D-aspartate receptor-antibody encephalitis 2 years ago, presented with a relapse of anti-N-methyl-D-aspartate receptor-antibody encephalitis characterized by recurrent seizures, mutism, and cognitive abnormalities.
Rituximab Induced Rare Cystic Lesion in Lungs in a Nephrotic Child: A Case Report.
Indian J Nephrol
May 2024
Division of Pediatric Nephrology, SVP Post Graduate Institute of Pediatrics (SVPPGIP) and Sriram Chandra Bhanja (SCB) Medical College, Cuttack, Odisha, India.
Article Synopsis
- Rituximab, an anti-CD20 monoclonal antibody, is commonly used for B-cell lymphomas and has recently been used for treating frequent relapsing nephrotic syndrome, showing a good safety profile with rare lung-related side effects.
- This report presents a unique case of a 9-year-old boy who developed lung injury after receiving rituximab, initially treated with various antibiotics due to suspected infection, but showed no improvement.
- After establishing a link between the medication and symptoms, the patient's lung issues were resolved with steroid therapy, marking it as the first documented instance of rituximab-induced lung cystic lesions in India.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!